【passpass】評論

(C) exemestane歐女士是乳腺癌的患者，而雌激素受體（estrogen receptor，ER）呈陽性。在這種情況下，荷爾蒙治療常被使用來降低雌激素的影響。Exemestane 是一種非競爭性雌激素合成酶抑制劑，常用於乳腺癌的荷爾蒙治療。

【IG:Pharmabook】評論

10th pharmacotherapy p.2207 CASE 93-4, QUESTION 2:Aromatase inhibitor(AI)常常是轉移性乳癌的一線治療分為非類固醇類AI (anastrozole) 與類固醇類AI (exemestane)若使用其中一類型的AI失敗，則可以選擇另一個類型的AIEX：用非類固醇類AI (anastrozole) 失敗，可嘗試類固醇類AI (exemestane)若仍失敗則可以嘗試其他機轉的藥物 (D)fulvestrant ：ER down regulator，與 ER 結合，使 estrogen 數目下降，用於tamoxifen失敗後的轉移性乳癌若還是失敗，則繼續考慮使用後線的(B)megestrol megestrol acetate, high-dose estrogens, or androgens Aromatase inhibitors are indicated for use in first-line therapy in the metastatic setting. If an AI is chosen as the first-line agent in the metastatic setting, use of another AI after progression would include one from another category (i.e., nonsteroidal vs. steroidal AI). For example, if anastrozole was used as first-line therapy for metastatic disease, then when the patient progresses, exemestane can be used T.R. was started on anastrozole therapy. She could have been initiated on any of the AIs. If her disease progresses, options include sequential exemestane, then fulvestrant, and then other agents such as megestrol acetate, high-dose estrogens, or androgens.